Literature DB >> 16493386

Residual neuromuscular blockade: incidence, assessment, and relevance in the postoperative period.

G S Murphy1.   

Abstract

The residual effects of neuromuscular blocking agents may persist into the early postoperative recovery period, even when neuromuscular blockade is carefully monitored and reversed in the operating room. Recent data suggest that mild degrees of residual paresis (train-of-four TOF ratios of 0.7-0.9) may be associated with significant impairment of respiratory and pharyngeal muscle function. Therefore, the new gold standard reflecting acceptable neuromuscular recovery is a TOF ratio > or =0.9. Several investigations have demonstrated that many patients continue to arrive in the postanesthesia care unit with TOF ratios <0.7-0.9. Several techniques may be used to reduce the risk of postoperative residual paresis, which include avoidance of long-acting muscle relaxants, use of neuromuscular monitoring in the operating room, routine reversal of neuromuscular blockade at a TOF count of 2-3, and early administration of reversal agents. Careful management of neuromuscular blockade may limit the occurrence of adverse events associated with residual postoperative paralysis. Large-scale outcome studies are needed to clearly define the impact of residual neuromuscular block on major morbidity and mortality in surgical patients.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16493386

Source DB:  PubMed          Journal:  Minerva Anestesiol        ISSN: 0375-9393            Impact factor:   3.051


  19 in total

Review 1.  Efficacy and safety of sugammadex versus neostigmine in reversing neuromuscular blockade in adults.

Authors:  Ana-Marija Hristovska; Patricia Duch; Mikkel Allingstrup; Arash Afshari
Journal:  Cochrane Database Syst Rev       Date:  2017-08-14

2.  Lower intra-abdominal pressure has no cardiopulmonary benefits during laparoscopic colorectal surgery: a double-blind, randomized controlled trial.

Authors:  Youn Joung Cho; Hyesun Paik; Seung-Yong Jeong; Ji Won Park; Woo Young Jo; Yunseok Jeon; Kook Hyun Lee; Jeong-Hwa Seo
Journal:  Surg Endosc       Date:  2018-05-14       Impact factor: 4.584

3.  Safety, tolerability and pharmacokinetics of sugammadex using single high doses (up to 96 mg/kg) in healthy adult subjects: a randomized, double-blind, crossover, placebo-controlled, single-centre study.

Authors:  Pierre A M Peeters; Michiel W van den Heuvel; Emiel van Heumen; Paul C C M Passier; Jean M W Smeets; Thijs van Iersel; Alex Zwiers
Journal:  Clin Drug Investig       Date:  2010       Impact factor: 2.859

4.  ROUTINE USE OF SUGAMMADEX DOES NOT SHORTEN PACU LENGTH OF STAY: A PROSPECTIVE DOUBLE-BLINDED RANDOMIZED CONTROLLED TRIAL.

Authors:  Germán Echeverry; Lily Polskin; Luis E Tollinche; Kenneth Seier; Kay See Tan; Patrick J McCormick; Gregory W Fischer; Florence M Grant
Journal:  Perioper Care Oper Room Manag       Date:  2021-07-16

Review 5.  Sugammadex: a review of its use in anaesthetic practice.

Authors:  Lily P H Yang; Susan J Keam
Journal:  Drugs       Date:  2009       Impact factor: 9.546

6.  Effect of Concurrent Lidocaine, Remifentanil and Methylprednisolone Use on the Clinical Effect of Sugammadex under General Anaesthesia in Rats.

Authors:  Tünay Kandemir; Erbin Kandemir; Tuğba Aşkın; Selda Muslu; Gonca Oğuz Tuncel; Süheyla Ünver
Journal:  Turk J Anaesthesiol Reanim       Date:  2019-05-22

7.  A Clinical and Budgetary Impact Analysis of Introducing Sugammadex for Routine Reversal of Neuromuscular Blockade in a Hypothetical Cohort in the US.

Authors:  Yiling Jiang; Lori D Bash; Leif Saager
Journal:  Adv Ther       Date:  2021-04-19       Impact factor: 3.845

8.  A survey of the current use of neuromuscular blocking drugs among the Middle Eastern anesthesiologists.

Authors:  Abdelazeem Eldawlatly; Mohamed R El-Tahan
Journal:  Saudi J Anaesth       Date:  2013-04

9.  Discovery, development, and clinical application of sugammadex sodium, a selective relaxant binding agent.

Authors:  Mark Welliver; John McDonough; Nicholas Kalynych; Robert Redfern
Journal:  Drug Des Devel Ther       Date:  2009-02-06       Impact factor: 4.162

10.  Intermediate acting non-depolarizing neuromuscular blocking agents and risk of postoperative respiratory complications: prospective propensity score matched cohort study.

Authors:  Martina Grosse-Sundrup; Justin P Henneman; Warren S Sandberg; Brian T Bateman; Jose Villa Uribe; Nicole Thuy Nguyen; Jesse M Ehrenfeld; Elizabeth A Martinez; Tobias Kurth; Matthias Eikermann
Journal:  BMJ       Date:  2012-10-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.